Introduction
How does the protease thrombin activate platelets and other cells? This question presents intriguing issues from both basic scientific and clinical perspectives. From a basic view, the fact that thrombin is a protease raises the possibility of a novel proteolytic mechanism of receptor activation. From a clinical view, thrombin regulates hemostasis and thrombosis. Moreover, a host of thrombin actions on cells have been defined in vitro; in vivo these actions may be critical for both normal responses to wounding and for pathological vascular events. An understanding of the mechanism of thrombin-induced cell activation promises reagents for identifying thrombin's role in cellular responses in vivo and possibly new therapeutics.
In this Perspectives, we review the recent cloning and characterization of a platelet thrombin receptor in our laboratory (1) . Identification ofthe thrombin receptor did reveal a unique proteolytic mechanism of receptor activation, and led to the development of a novel agonist peptide which activates the thrombin receptor independent of thrombin and thrombin's protease activity. This agonist peptide is a useful new tool for addressing the role of thrombin receptor activation in cellular responses. It is our hope that having the cloned receptor in hand will also allow the development of thrombin receptor antagonists. Such reagents will define the role of thrombin receptor activation in normal and disease processes in vivo, and may provide the basis for a new class of antithrombotic or antiproliferative pharmaceuticals. Cell-activatingfunctions ofthrombin In addition to cleaving fibrinogen to fibrin, thrombin exhibits important "cell-activating" functions ( Fig. 1 ; reviewed in ref.
2). First and foremost, thrombin is the most potent stimulator ofplatelet aggregation (3) , a thrombin activity probably critical in arterial thrombosis (see below). A variety of other thrombin activities on cells has been defined, largely in vitro. Thrombin is chemotactic for monocytes (4), mitogenic for lymphocytes and for mesenchymal cells including vascular smooth muscle cells (5, 6) , and has a number ofeffects upon the vascular endo-thelium. These include stimulating endothelial production of prostacyclin (7) , platelet-activating factor (8) , plasminogen activator-inhibitor (9) , and the potent smooth muscle cell mitogen platelet-derived growth factor (10) . Thrombin also induces neutrophil adherence to the vessel wall by an endothelial-dependent mechanism (1 1), probably by causing surface expression of GMP-140 (12) . Teleologically, these multiple cell-activating functions of thrombin may be viewed as orchestrating the response to vascular injury, potentially mediating not only hemostatic but perhaps inflammatory and proliferative or reparative responses. Whether these disparate actions of thrombin are all important in vivo remains to be defined.
Thrombin activities that would not necessarily be associated with vascular injury have also been described. The surprising inhibitory effects of thrombin on neurite outgrowth (13, 14) and the apparent expression ofprothrombin mRNA in brain (15) (16) (17) (18) (19) (20) . In general, the importance ofthrombin in mediating nonthrombotic responses in vivo remains to be defined. In particular, whether thrombin plays a significant role in inflammatory or proliferative responses to vascular injury remains to be tested. A recent study using recombinant hirudin does suggest a role for thrombin in mediating restenosis after angioplasty in one animal model (21) . It is hoped that the characterization of the platelet thrombin receptor will permit the development of thrombin receptor blockers to directly address the importance of thrombin-induced cell activation in vivo. also has a number of effects on the vascular endothelium, including stimulating expression of the neutrophil adhesive protein GMP-140 on the endothelial surface as well as the production of the potent smooth muscle cell mitogen, platelet-derived growth factor (PDGF). As discussed in the text, these multiple activating functions of thrombin may be viewed teleologically as orchestrators of hemostatic, inflammatory, and reparative responses to vascular injury.
tor, and combinations thereof (2, 22) . Traditional ligand binding approaches to identify a functional thrombin receptor identified proteins which bind thrombin but have no apparent signalling function (23, 24) . In fact, because modified thrombins that lack both agonist and antagonist activity do bind to platelets in a manner indistinguishable from wild type thrombin (25-29), it has not been possible to conclude that the sites identified in binding studies are related to the functional thrombin receptor. Because of difficulties with the classical binding approach and the undefined nature of thrombin-receptor interaction, we adopted an expression cloning approach which followed thrombin-induced responses in Xenopus oocytes expressing exogenous mRNA to isolate a functional human thrombin receptor cDNA (1). This strategy was based on studies by Masu and colleagues who had successfully used expression cloning in Xenopus oocytes to isolate a cDNA for the substance K receptor (30) . The cloning ofthe thrombin receptor was described in detail elsewhere (1) . The deduced amino acid sequence of this clone revealed a novel member of the seven transmembrane receptor family. Closest relatives included receptors for small peptides, substance P and substance K (1), suggesting that the thrombin receptor is peptide receptor-like. This analogy was a useful hint at the outset of the structure-function work described below.
Closer inspection ofthe receptor's amino acid sequence was revealing in the light of a large body of literature on thrombin action. Thrombin cleaves peptides after arginines (31 Figs. 2 and 3 ). This site resembled the known thrombin cleavage site found in the thrombin-activated zymogen protein C (LDPR/I) (32) . Carboxyl to this putative cleavage site lies a receptor domain resembling the carboxyl tail of the polypeptide hirudin, a leech-derived anticoagulant which binds thrombin with remarkable avidity. To put these sequence observations into context, thrombin possesses an extended substrate binding surface that recognizes residues both amino and carboxyl to a substrate's cleavage site (33) (Fig. 2) .
Part ofthis extended substrate binding surface, the anion-binding exosite (Fig. 2) , is important for thrombin's ability to activate its receptor (1, 34) . Because the carboxyl tail of hirudin interacts with thrombin's anion-binding exosite (35) , the presence of the hirudin-like sequence carboxyl to the putative thrombin cleavage site within the thrombin receptor's amino terminal extension suggested that receptor proteolysis at this cleavage site might be important in receptor activation (Fig. 2) .
We evaluated the importance of the putative cleavage site at R41/S42 by changing the arginines in the receptor's amino terminal extension to alanines, a maneuver designed to render each site uncleavable by thrombin. 
Modelfor thrombin receptor activation
The studies described above suggest that thrombin receptor activation proceeds by the novel mechanism depicted in Fig. 3 . Thrombin cleaves its receptor after arginine 41 in the receptor's amino terminal extension, exposing a new amino terminus that functions as a tethered peptide ligand for the receptor. The new amino terminus then binds to an as yet undefined receptor site, effecting receptor activation (1) .
Recent studies buttress this model (38, 39) . Replacing the receptor's thrombin cleavage site (LDPR/S) with that for enterokinase (DDDDK/S) completely switched the receptor's specificity, creating a functional "enterokinase receptor" that was fully activatable by enterokinase but unresponsive to thrombin (38) . These results strongly suggest that receptor proteolysis that unmasks the amino terminus beginning a position 42 (SFLL. . .) is sufficient for receptor activation (38) . No special "hormone-like" properties ofthrombin need to be invoked for activation of this receptor.
Additional studies have shown the receptor's hirudin-like sequence can indeed bind thrombin's anion-binding exosite (38, 39) . Detailed mutagenesis studies have defined the specific residues important in this interaction and strengthened the analogy between the receptor's anion binding exosite binding functions as a tethered peptide ligand, binding to an as yet undefined pocket, thereby effecting receptor activation (1) (reprinted with permission from Nature [38] ). domain and hirudin's carboxyl tail (38) . These relationships are cartooned in Fig. 2 B.
Issues and opportunities The studies presented above raise provocative questions and present opportunities at both basic mechanistic and clinical levels. Some of these are discussed below.
From a basic perspective, we have learned a great deal about how the receptor senses thrombin in its environment, i.e., via the binding and proteolytic events described above. More detailed information regarding thrombin-receptor interaction will undoubtedly come from crystallographic studies. The rapid unravelling of the mechanism by which thrombin activates its receptor "fell out" of an analysis of the thrombin receptor's amino acid sequence. Existing literatures on thrombin structure/function and on seven transmembrane domain receptors allowed us to identify the receptor's thrombin cleavage site and binding domains and to frame the thrombin receptor as a "peptide receptor", leading naturally to the model depicted in Figs. 2 and 3. Many questions remain unanswered. Where does the agonist peptide domain unmasked by receptor proteolysis bind, and how does this binding event lead to a transmembrane signal that allows the receptor to talk to intracellular signalling molecules (Fig. 3) 3, 22) . Does GPIb promote activation of the cloned receptor by binding thrombin and localizing it to the cell surface (3, 20, 22) ? A body ofcircumstantial evidence does support this model, but direct demonstration ofan adjunctive role for GPIb in thrombin signalling using, for example, GPIb expressed in null cells is lacking at this time. As an alternative hypothesis, could GPIb serve as a sink for thrombin? Perhaps, at low ambient thrombin concentrations, GPIb might bind thrombin long enough to allow inactivation by antithrombin III. By preventing thrombin interaction with the receptor and receptor desensitization by trace levels of thrombin in the normal circulation, such a mechanism might also explain the defect in thrombin signalling seen in Bernard-Souher. Lastly, it is possible that thrombin binding to GPIb serves an independent, as yet undefined function.
From the pathophysiologic and clinical perspective, these studies suggest a number ofpaths to novel reagents that will be useful in defining the role of thrombin receptor activation in vivo. Receptor-based peptides that bind and inhibit various thrombin functions have been produced (38, 39, 41) . These are novel among thrombin inhibitor peptides (42) in that they are based on human sequence; whether this will translate into any practical clinical benefit over other agents in development is unknown.
More novel and useful would be thrombin receptor 
